AstraZeneca’s breast cancer drug given priority review by FDA
A priority review means regulators will come to a conclusion earlier than usual and Astra expects to hear back in the first quarter of 2018
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 40 of 55
AstraZeneca’s Imfinzi cancer drug clears another regulatory hurdle
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
AstraZeneca rises as Credit Suisse praises recent progress, hikes price target by £10
CS analysts say AstraZeneca is finally starting to get over the patent expiries of several blockbuster drugs, including Crestor, Seroquel and Nexium
Koovs jumps on partnership deal with online clothing retailer N Brown
A look at some of the biggest risers and fallers today in London
FTSE 100 closes in negative territory despite resource stock gains
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
AstraZeneca continues to face pricing pressures and competitive headwinds, says ShoreCap
ShoreCap cut its price target to 4,600p from 5,154p on AstraZeneca and left its rating at ‘hold’.
AstraZeneca’s Tagrisso lung cancer drug granted ‘breakthrough therapy designation’ by US FDA
"The Breakthrough Therapy Designation acknowledges not only Tagrisso's potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease”
SynairGen to target COPD with inhaled interferon beta treatment
"A COPD programme is now both highly attractive and economically viable"
Exane BNP Paribas swoons over AstraZeneca’s drugs pipeline as it upgrades to 'outperform'
The pipeline isn’t a pipe dream any more, so say Exane analysts
Bernstein ups stance on AstraZeneca to ‘outperform’, citing big pipeline, takeover possibilities
Bernstein’s analyst said they consider AstraZeneca as a “pipeline-driven, return-to-growth story”, pointing that the group has one of the fullest phase 3 trial pipelines
AstraZeneca offloads remaining rights to anaesthetic portfolio to Aspen for US$766mln
“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas”
Shire, AstraZeneca and GSK in the red as JP Morgan looks at risks facing pharmaceutical sector
Shire remains the "standout stock" as it has an "extremely compelling valuation”, according to JP Morgan
Teva Pharmaceutical names Danish industry veteran Kare Schultz as its new chief executive
The new chief executive joins Teva - the world's biggest seller of generics medicines - from Denmark's H. Lundbeck A/S, where he has been president and CEO since May 2015
AstraZeneca lung cancer trial results impress but risks remain, analysts say
Analysts see the results of phase III trials for Imfinzi and Tagrisso as a positive development for AstraZeneca but have raised concerns about other areas of the business
AstraZeneca gains after reporting positive results from two trials of lung cancer treatments
AstraZeneca is making progress in trials of its lung cancer treatments
FTSE 100 closes almost 36pts up as traders buy back in
The blue chip index closed out almost 36 points higher at 7,413
FTSE 100 trims losses
The FTSE 100 retreated as investors worry about Hurricane Irma, while mixed economic statistics raised fresh concerns over the UK economy.
Celgene says US FDA places holds on clinical trials for cancer checkpoint inhibitor being developed with AstraZeneca
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
Natixis upgrades AstraZeneca to ‘buy’ on prospect of positive results from key MYSTIC lung cancer trial
The Natixis analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential”
FTSE 100 closes lower as traders continue to fret about North Korea
FTSE 100 closed down 18.79 at 7,354, while the FTSE 250 lost over 74 points at 19,652.